Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

Journal of Lipid Research

Volumn 55, Issue 10, 2014, Pages 2103-2112

  Kühnast, Susan ^a,b   Van Der Hoorn, José W A ^a,b   Pieterman, Elsbet J ^a   Van Den Hoek, Anita M ^a   Sasiela, William J ^c   Gusarova, Viktoria ^c   Peyman, Anusch ^d   Schäfer, Hans Ludwig ^d   Schwahn, Uwe ^d   Jukema, J Wouter ^b   Princen, Hans M G ^a  

^a TNO   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

3Leiden.CETP mice; APOE; Atorvastatin; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN E; ATORVASTATIN; BILE ACID; CHOLESTEROL; COLLAGEN; LOW DENSITY LIPOPROTEIN RECEPTOR; STEROL; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SAFETY; FAT CONTENT; FEMALE; LIPID BLOOD LEVEL; MONOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; SMOOTH MUSCLE FIBER; ANIMAL; GENETICS; HUMAN; MACROPHAGE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; MICE; MICE, TRANSGENIC; MONOCYTES;

EID: 84907525325     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M051326     Document Type: Article

References (49)

1. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2007. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32: 71-77.
2. Seidah, N. G., and A. Prat. 2012. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11: 367-383.
3. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
4. Lambert, G., B. Sjouke, B. Choque, J. J. Kastelein, and G. K. Hovingh. 2012. The PCSK9 decade. J. Lipid Res. 53: 2515-2524.
5. Benn, M., B. G. Nordestgaard, P. Grande, P. Schnohr, and A. Tybjaerg-Hansen. 2010. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J. Am. Coll. Cardiol. 55: 2833-2842.
6. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
7. Cariou, B., K. Ouguerram, Y. Zair, R. Guerois, C. Langhi, S. Kourimate, I. Benoit, C. Le May, C. Gayet, K. Belabbas, et al. 2009. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 29: 2191-2197.
8. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116: 2995-3005.
9. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101: 7100-7105.
10. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
11. Denis, M., J. Marcinkiewicz, A. Zaid, D. Gauthier, S. Poirier, C. Lazure, N. G. Seidah, and A. Prat. 2012. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 125: 894-901.
12. Davidson, M. H., K. C. Maki, T. A. Pearson, R. C. Pasternak, P. C. Deedwania, J. M. McKenney, G. C. Fonarow, D. J. Maron, B. J. Ansell, L. T. Clark, et al. 2005. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96: 556-563.
13. Mihaylova, B., J. Emberson, L. Blackwell, A. Keech, J. Simes, E. H. Barnes, M. Voysey, A. Gray, R. Collins, and C. Baigent. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 380: 581-590.
14. Cannon, C. P., E. Braunwald, C. H. McCabe, D. J. Rader, J. L. Rouleau, R. Belder, S. V. Joyal, K. A. Hill, M. A. Pfeffer, and A. M. Skene. 2004. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350: 1495-1504.
15. LaRosa, J. C., S. M. Grundy, D. D. Waters, C. Shear, P. Barter, J. C. Fruchart, A. M. Gotto, H. Greten, J. J. Kastelein, J. Shepherd, et al. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352: 1425-1435.
16. Ridker, P. M., E. Danielson, F. A. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, et al. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359: 2195-2207.
17. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., and N. J. Stone. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 110: 227-239.
18. Reiner, Z., A. L. Catapano, G. De Backer, I. Graham, M. R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, et al. 2011. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 32: 1769-1818.
19. Expert Dyslipidemia Panel, Grundy SM. 2013. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. J. Clin. Lipidol. 7: 561-565.
20. Dubuc, G., A. Chamberland, H. Wassef, J. Davignon, N. G. Seidah, L. Bernier, and A. Prat. 2004. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24: 1454-1459.
21. Mayne, J., T. Dewpura, A. Raymond, M. Cousins, A. Chaplin, K. A. Lahey, S. A. Lahaye, M. Mbikay, T. C. Ooi, and M. Chretien. 2008. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 7: 22.
22. Careskey, H. E., R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad. 2008. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49: 394-398.
23. Stein, E. A., S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan, W. B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366: 1108-1118.
24. Stein, E. A., D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, R. Dufour, R. Wu, and R. Pordy. 2012. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 380: 29-36.
25. McKenney, J. M., M. J. Koren, D. J. Kereiakes, C. Hanotin, A. C. Ferrand, and E. A. Stein. 2012. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59: 2344-2353.
26. Roth, E. M., J. M. McKenney, C. Hanotin, G. Asset, and E. A. Stein. 2012. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367: 1891-1900.
27. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26: 2552-2559.
28. de Knijff, P., A. M. van den Maagdenberg, A. F. Stalenhoef, J. A. Leuven, P. N. Demacker, L. P. Kuyt, R. R. Frants, and L. M. Havekes. 1991. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J. Clin. Invest. 88: 643-655.
29. van Vlijmen, B. J., A. M. van den Maagdenberg, M. J. Gijbels, H. van der Boom, H. HogenEsch, R. R . Frants, M. H. Hofker, and L. M . Havekes. 1994. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 93: 1403-1410.
30. Zadelaar, S., R. Kleemann, L. Verschuren, J. de Vries-van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra. 2007. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27: 1706-1721.
31. de Haan, W., C. C. van der Hoogt, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, H. M. Princen, J. A. Romijn, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2008. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE∗3-Leiden.CETP mice. Atherosclerosis. 197: 57-63.
32. van der Hoogt, C. C., W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. Princen, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2007. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J. Lipid Res. 48: 1763-1771.
33. van der Hoorn, J. W., W. de Haan, J. F. Berbee, L. M. Havekes, J. W. Jukema, P. C. Rensen, and H. M. Princen. 2008. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice. Arterioscler. Thromb. Vasc. Biol. 28: 2016-2022.
34. de Haan, W., J. de Vries-van der Weij, J. W. van der Hoorn, T. Gautier, C. C. van der Hoogt, M. Westerterp, J. A. Romijn, J. W. Jukema, L. M. Havekes, H. M. Princen, et al. 2008. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 117: 2515-2522.
35. Kawashiri, M. A., J. Kobayashi, A. Nohara, T. Noguchi, H. Tada, C. Nakanishi, A. Inazu, H. Mabuchi, and M. Yamagishi. 2011. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study. Clin. Chim. Acta. 412: 1068-1075.
36. Kühnast, S., J. W. van der Hoorn, A. M. van den Hoek, L. M. Havekes, G. Liau, J. W. Jukema, and H. M. Princen. 2012. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE∗3Leiden.CETP transgenic mice with or without treatment with atorvastatin. J. Hypertens. 30: 107-116.
37. Delsing, D. J., E. H. Offerman, W. van Duyvenvoorde, H. van der Boom, E. C. de Wit, M. J. Gijbels, A. van der Laarse, J. W. Jukema, L. M. Havekes, and H. M. Princen. 2001. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE∗3-Leiden mice. Circulation. 103: 1778-1786.
38. Stary, H. C., A. B. Chandler, R. E. Dinsmore, V. Fuster, S. Glagov, W. Insull, Jr., M. E. Rosenfeld, C. J. Schwartz, W. D. Wagner, and R. W. Wissler. 1995. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 15: 1512-1531.
39. Verschuren, L., R. Kleemann, E. H. Offerman, A. J. Szalai, S. J. Emeis, H. M. Princen, and T. Kooistra. 2005. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E∗3-Leiden transgenic mice. Arterioscler. Thromb. Vasc. Biol. 25: 161-167.
40. Kühnast, S., M. C. Louwe, M. M. Heemskerk, E. J. Pieterman, J. B. van Klinken, S. A. van den Berg, J. W. Smit, L. M. Havekes, P. C. Rensen, J. W. van der Hoorn, et al. 2013. Niacin reduces atherosclerosis development in APOE∗3Leiden.CETP mice mainly by reducing nonHDL-cholesterol. PLoS ONE. 8: e66467.
41. Verschuren, L., J. de Vries-van der Weij, S. Zadelaar, R. Kleemann, and T. Kooistra. 2009. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE∗3Leiden mice: time course and mechanisms. J. Lipid Res. 50: 301-311.
42. Stein, E. A., and G. D. Swergold. 2013. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr. Atheroscler. Rep. 15: 310.
43. Parker, R. A., R. Garcia, C. S. Ryan, X. Liu, P. Shipkova, V. Livanov, P. Patel, and S. P. Ho. 2013. Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression. J. Lipid Res. 54: 2400-2409.
44. Le May, C., J. M. Berger, A. Lespine, B. Pillot, X. Prieur, E. Letessier, M. M. Hussain, X. Collet, B. Cariou, and P. Costet. 2013. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33: 1484-1493.
45. Libby, P., and W. Sasiela. 2006. Plaque stabilization: can we turn theory into evidence? Am. J. Cardiol. 98: 26P-33P.
46. Moore, K. J., F. J. Sheedy, and E. A. Fisher. 2013. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol. 13: 709-721.
47. Swirski, F. K., P. Libby, E. Aikawa, P. Alcaide, F. W. Luscinskas, R. Weissleder, and M. J. Pittet. 2007. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117: 195-205.
48. Libby, P. 2013. Mechanisms of acute coronary syndromes and their implications for therapy. N. Engl. J. Med. 368: 2004-2013.
49. Abela, G. S. 2010. Cholesterol crystals piercing the arterial plaque and intima trigger local and systemic inflammation. J. Clin. Lipidol. 4: 156-164.